Tuesday, Jun 14, 2022 8:00a -
Thursday, Jun 16, 2022 6:00p

Wyndham Boston Beacon Hill
5 Blossom Street
Boston, Massachusetts 02114

EventScheduled OfflineEventAttendanceMode

$Conference + Workshop Day - Drug Developer USD 3946.00, Conference Only - Drug Developer USD 2599.00, Conference + Workshop Day - Academic USD 3246.00, Conference Only - Academic USD 2199.00, Conference + Workshop Day - Service Provider USD 4846.00, Conference Only - Service Provider USD 3199.00

Lectures & Conferences

Event website:

Returning in 2022, the Tumor Myeloid-Directed Therapeutics Summit is the only industry-focused meeting dedicated to unlocking novel therapeutic potential through the myeloid compartment.

This is your ultimate forum to identify, validate, and clinically progress myeloid targets to expand the oncologists toolkit and realize better responses by engaging myeloid anti-tumor function.

Designed for experts working directly on myeloid-directed therapies, and those in adjacent immuno-oncology fields, from cell therapy to checkpoint and engager development.

If you're scratching your head in attempt to enhance efficacy in solid tumors and overcome barriers in the microenvironment, this is your 500-foot view of the intricate pathways, interactions, and novel target development in the tumor microenvironment

Deep-dive into myeloid biology, guided by 27+ industry Gurus from the likes of Pionyr Therapeutics, Gilead Sciences, Merck, Verseau Therapeutics, Carisma Therapeutics, Pfizer and many more

With targets such as TREM1 and TREM2 making waves in the clinic, analysis of CD47 candidates back-translating to next-generation therapies, and novel dendritic cell candidates such as FTL3 in development, this 3-day myeloid extravaganza is unmissable for anyone looking to unlock better therapeutic potential through the myeloid compartment.

Tickets https://go.evvnt.com/1007623-1?pid=5248
Brochure https://go.evvnt.com/1007623-3?pid=5248

Speakers: Barbara Cipriani Head of Biology Pathios Therapeutics, Ella Ioffe Director Immuno- Oncology Regeneron Pharmaceuticals, Jasper Mullenders Director Translational Research Scenic Biotech, Jeffrey Pollard Director of the MRC Center for Reproductive Health The University of Edinburgh, Johan Baeck SVP Clinical Development & Medical Affairs Jounce Therapeutics, Joshua Pollack Associate Director, Bioinformatics & Translational Biology Pionyr Therapeutics, Judith Varner Professor of Pathology University of California San Diego, Julien Faget Researcher INSERM, Michelle Kuhne Director Gilead Sciences, Peter Ellmark CSO Alligator Biosciences, Tatiana Novobrantseva Co-Founder & CSO Verseau Therapeutics, Yan Chen President & CEO Elpis Biopharmaceuticals, Aram Mangasarian CEO NOXXON, Barbara Platzer Senior Principal Scientist Novartis Institutes for BioMedical Research, Carol O’Hear CP Clinical Development Gilead Sciences, Carola Ries CSO Macomics, Daniel Blumenthal Senior Scientist Carisma Therapeutics, George Fromm VP R&D Shattuck Labs, Kareem Azab Associate Professor, Cancer Biology Division, Department of Radiation Oncology Washington University St. Louis, Leonard Reyno CMO Pionyr Therapeutics, Meenal Datta Assistant Professor, Aerospace & Mechanical Engineering University of Notre Dame, Michael Curran Associate Professor, Dept. of Immunology & Co-Founder, ORBIT Platform MD Anderson Cancer Center, Murali Gururajan Director Cancer Immunology Discovery Pfizer, Nagy Habib Founder & Head of R&D MiNa Therapeutics, Nicolas Poirier CSO OSE Immunotherapeutics, Roy Noy Senior Staff Scientist Regeneron Pharmaceuticals, Xin Yu Director, Oncology Discovery Merck

Share this event

Add to:

14/06/2022 08:00:00 16/06/2022 18:00:00 America/New_York 2nd Tumor Myeloid-Directed Therapies Summit Returning in 2022, the Tumor Myeloid-Directed Therapeutics Summit is the only industry-focused meeting dedicated to unlocking novel therapeutic potential through the myeloid compartment. This is... Wyndham Boston Beacon Hill, Boston, Massachusetts 02114 false DD/MM/YYYY